Delcath Expands Phase III Trial For Metastatic Melanoma To Include University Of Maryland Medical Center
Delcath Systems, Inc. (Nasdaq: DCTH) announced that the Institutional Review Board (IRB) of the University of Maryland Medical Center (UMMC) has approved UMMC’s participation in the Phase III study of the Company’s Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan to treat inoperable metastatic melanoma in the liver.
This post is an original post by ScienceDaily: Skin Care News
Posted: April 26th, 2008 under skin health.
Comments: none
Write a comment